SciBase Launches SEK 58M Rights Issue to Fuel US Expansion
Event summary
- SciBase resolves a SEK 57.5M rights issue with preferential rights for shareholders, set to close by 29 September 2026.
- Existing shareholders and Bergs Securities commit to cover the entire issue, with subscription undertakings totaling SEK 33.3M and a guarantee intention of SEK 24.2M.
- Proceeds will primarily fund US commercialization efforts, including reimbursement initiatives and production capacity expansion.
- The rights issue could dilute shares by up to 27%, with an additional 1.4% dilution possible if guarantee compensation is paid in shares.
- CEO Pia Renaudin highlights strong US momentum in melanoma diagnostics and collaboration potential with Castle Biosciences in atopic dermatitis.
The big picture
SciBase's rights issue reflects its strategic pivot toward the US market, where it has seen 68% revenue growth in H1 2026. The capital raise underscores the competitive dynamics in dermatology diagnostics, particularly as AI-driven platforms like Nevisense vie for market share. The company's focus on reimbursement and production capacity highlights the operational challenges of scaling in a highly regulated sector.
What we're watching
- US Market Penetration
- Whether SciBase can secure reimbursement approval in early 2027 and sustain its 79% year-over-year growth in US melanoma diagnostics.
- Collaboration Expansion
- How the partnership with Castle Biosciences will develop beyond atopic dermatitis into other skin disease diagnostics.
- Leadership Transition
- The impact of an impending CEO change on SciBase's commercial development and cost control strategies.
Related topics